Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement
Agreement could boost fish populations, improve ocean health, and help coastal communities
PARIS, July 15, 2021 /PRNewswire/ -- SKEMA Business School announces the signing of a new agreement with New York University School of Professional Studies (NYU SPS) Division of Programs in Business (DPB).
LAUSANNE, Switzerland, July 12, 2021 /PRNewswire/ -- ActLight, the Swiss technology firm known for its best-in-class signal-to-noise ratio photodiodes, announced today that it has signed the second service agreement based on its Single Photon Sensitivity technology with a leading company in the sensors market.
DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.
SORCIA has reached an agreement for over 2000 hectares to exploit lithium with innovative sustainable technology
CINCINNATI, June 24, 2021 /PRNewswire/ -- Standard Textile Co., Inc. and Küçükçalık today announce they have entered into a joint venture agreement. The joint venture agreement brings together the specialized expertise and knowledge of two leading textile manufacturing companies to expand their product portfolio and accelerate growth in the healthcare, hospitality, and consumer markets.
LONDON, June 22, 2021 /PRNewswire/ -- CommerceHub, a leading ecommerce enablement platform of thousands of retailers, brands and suppliers, today announced that Foot Locker Europe has signed a four-year agreement to help expand its product assortment and create a more efficient supply chain for its Foot Locker and Sidestep brands across eighteen European countries.
Company completes first development agreement in Romania as part of larger international growth efforts
CHANGZHOU, China, June 4, 2021 /PRNewswire/ -- On June 4, Jiangsu Seraphim Solar System Co., Ltd. (hereinafter referred to as Seraphim), a global leading PV module manufacturer, announced that it has entered into an agreement for supply of 1GW PV modules with Rodina Energy Group LLC (hereinafter referred to as Rodina), a global EPC and O&M service provider. Both parties agreed to work together to bring high quality solar products and services to global clients in order to gain a larger share of o...
SEOUL, South Korea, May 18, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's largest molecular diagnostics firm, will be supplying COVID-19 diagnostic kits worth over $4.8 million to the Kuwaiti government.
SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021.
VANCOUVER, BC, March 23, 2021 /PRNewswire/ -- Loop Energy (TSX: LPEN) and Rheintal-Transporte announced today an agreement for the development and supply of heavy-duty hydrogen fuel cell range extension solutions for battery electric trucks in Europe.
SHANGHAI, March 16, 2021 /PRNewswire/ -- Shanghai Electric (the "Company") (SEHK: 02727, SSE: 601727), the world's leading manufacturer and supplier of electric power generation equipment, industrial equipment, and integration services, joined hands with the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences (the "Dalian Institute") to inaugurate the Proton Exchange Membrane (PEM) Hydrogen Production Technology R&D Center on March 4. The two parties signed a project cooperati...
Agreement includes 10X15,000 TEU vessels, intended to meet the growing market demand in the Asia - US East Coast trade
SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced the companies will be expanding their manufacturing agreement...
STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Spada: "Un momento di dialogo e di confronto aperto ai soggetti istituzionali che hanno la responsabilità di intervenire con azioni di supporto"
NEW YORK and BLAINVILLE, QC, Nov. 30, 2020 /PRNewswire/ -- Today the Population Council and Duchesnay announce an exclusive license agreement to make ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive fully under a woman's control to protect against unintended pregnancy for up to a year, available in Canada, Europe, Latin America, Asia and other territories. This agreement is another step toward bringing contraceptive choice, convenience and con...
SUZHOU, China, Oct. 26, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively positioned in global markets against established treatments for the target indications.
